Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Debt
Debt-to-Equity Ratio3.14
Current Ratio2.68
Quick Ratio2.64
Price-To-Earnings
Trailing P/E Ratio-5.24
Forward P/E Ratio-11.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.20 million
Price / Sales61.04
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book29.61
Profitability
EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net Margins-146.27%
Return on Equity-367.92%
Return on Assets-112.75%
Miscellaneous
Employees318
Outstanding Shares38,030,000
Market Cap$1.70 billion
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) released its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.09. The biopharmaceutical company had revenue of $50.80 million for the quarter, compared to analyst estimates of $45.67 million. Puma Biotechnology had a negative net margin of 146.27% and a negative return on equity of 367.92%. During the same period last year, the firm earned ($1.38) earnings per share. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
9 analysts have issued 1 year price targets for Puma Biotechnology's shares. Their forecasts range from $77.00 to $164.00. On average, they anticipate Puma Biotechnology's stock price to reach $104.6667 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.
What is the consensus analysts' recommendation for Puma Biotechnology?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL) and Endo International (ENDP).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, CEO, Pres & Sec. (Age 48)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
- Dr. Richard P. Bryce MBChB, MRCGP, MFPM, Chief Medical & Scientific Officer (Age 61)
- Mr. Steven Lo, Chief Commercial Officer (Age 51)
- Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management
Has Puma Biotechnology been receiving favorable news coverage?
Media coverage about PBYI stock has trended somewhat positive recently, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Puma Biotechnology earned a media and rumor sentiment score of 0.13 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.65 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Puma Biotechnology.
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (8.73%), Orbimed Advisors LLC (7.19%), BlackRock Inc. (6.63%), FMR LLC (4.55%), Partner Fund Management L.P. (4.20%) and Jennison Associates LLC (2.52%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Which institutional investors are selling Puma Biotechnology stock?
PBYI stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Partner Fund Management L.P., Point72 Asset Management L.P., Voya Investment Management LLC, BNP Paribas Arbitrage SA, Eagle Asset Management Inc., Federated Investors Inc. PA and California Public Employees Retirement System. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.
Which institutional investors are buying Puma Biotechnology stock?
PBYI stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Jennison Associates LLC, Millennium Management LLC, Redwood Investments LLC, BlackRock Inc., FMR LLC, Fred Alger Management Inc. and Orbimed Advisors LLC. View Insider Buying and Selling for Puma Biotechnology.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $41.95.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $1.70 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
